Home|Journals|Articles by Year|Audio Abstracts
 

4 articles found.


Publishing Year(s)



Click to Change Year(s)

Journal(s)



Click to Change Journal(s)
  1. Synchronous invasive urothelial cell carcinoma of the bladder with chronic myeloid leukemia
    Syakri Syahrir, Muhammad Asykar Palinrungi, Prihantono Prihantono, Muhammad Faruk,
    International Journal of Surgery and Medicine. 2019; 5(4): 226-229.
  2. Effectiveness of using Solifenacin compared to Mirabegron after double-J stent installation for treatment of lower urinary tract symptoms (LUTS)
    Emmy Palinggi, Muhammad Asykar Palinrungi, Achmad M. Palinrungi, Arifin Seweng, Khoirul Kholis, Syakri Syahrir, Syarif Syarif, Muhammad Faruk
    Journal of Medical and Allied Sciences. 2020; 10(2): 115-120.
  3. Effectiveness of Tamsulosin compared with Mirabegron in treatment of Double-J Stent-Related Lower Urinary Tract Symptoms
    King Alexander, Achmad M. Palinrungi, Muhammad Asykar Palinrungi, Khoirul Kholis, Syakri Syahrir, Muhammad Faruk
    International Journal of Medical Reviews and Case Reports. 2020; 4(8): 8-13.
  4. Obesity Effect on Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) Value in Various Metabolic Syndrome (MS) Components
    Syahrir Parawansyah , Husaini Umar, Makbul Aman Mansyur, Syakib Bakri, Hasyim Kasim, Himawan Sanusi, Rahmawati Minhajat, Arifin Seweng,
    International Journal of Medical Reviews and Case Reports. 2019; 3(11): 671-675.


Online Article Submission
• ejmanager.com


ejPort - eJManager.com
Refer & Earn
JournalList
 About BiblioMed
License Information
Terms & Conditions
Privacy Policy
 Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.